Lazabemide (hydrochloride)

Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM) . Lazabemide inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease[1].

Product Specifications

CAS Number

[103878-83-7]

Product Name Alternative

Ro 19-6327 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lazabemide-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=NC=C(Cl)C=C1)NCCN.[H]Cl

Molecular Formula

C8H11Cl2N3O

Molecular Weight

236.10

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362-P403+P233-P405-P501

References & Citations

[1]Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12 (5) :1977-99.|[2]Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N- (2-aminoethyl) -p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50 (1) :97-102.|[3]Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62 (8) :727-37.|[4]Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50 (6) :357-62.